Comparative, randomized, open, crossover clinical trial to investigate adhesiveness of a newly developed Rotigotine 12 mg/24 h transdermal patch in patients with Parkinson’s disease

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521172-64-00

Acronym

1462rot25ct

Enrollment

Registered

2025-07-23

Start date

2026-01-05

Completion date

Unknown

Last updated

2025-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson's disease

Brief summary

Mean adhesion of Test at 23 h 55 min, Difference of adhesiveness (Test – Reference) at 23 h 55 min

Detailed description

Frequency of AESIs, Frequency of AEs

Interventions

DRUGROT-TDS

DRUGNeupro 8 mg/24 h transdermal patch

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Mean adhesion of Test at 23 h 55 min, Difference of adhesiveness (Test – Reference) at 23 h 55 min	—

Secondary

Measure	Time frame
Frequency of AESIs, Frequency of AEs	—

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026